Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

2018170 citationsJournal Articlehybrid Open Access

Authors

Michael Szarek · SUNY Downstate Health Sciences University

Harvey D. White · University of Auckland

Gregory G. Schwartz · University of Colorado Denver

Marco Alings · Amphia Ziekenhuis

Deepak L. Bhatt · Harvard University

Vera Bittner · University of Alabama at Birmingham

Chern‐En Chiang

Abstract

In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.

Topics & Keywords

Lipoproteins and Cardiovascular Health Health Systems, Economic Evaluations, Quality of Life Cardiac Imaging and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American College of Cardiology

Volume 73, Issue 4, pp. 387-396

DOI: 10.1016/j.jacc.2018.10.039

Field-Weighted Citation Impact: 25.37